Pharmaceutical

 Strategies to Increase the Value of Drug Therapy

Strategies to Increase the Value of Drug Therapy

Value is a concept that concerns all healthcare stakeholders.

Merck will evaluate Keytruda cancer combo therapy

Merck will collaborate with Syndax to evaluate the pairing of an anti-PD-1 therapy in Keytruda with HDAC inhibitor entinostat.

Bayer expands MIT/Harvard collaboration

The focus will now include cardiovascular disease.

Teva will acquire Auspex to fill Copaxone patent hole

Teva will acquire Auspex to fill Copaxone patent hole

By

The drugmaker known for its massive presence in generics purchased Auspex Pharmaceuticals to bolster its growing specialty business.

Horizon makes $1.1-billion rare-disease push

Horizon makes $1.1-billion rare-disease push

By

Horizon Pharma's purchase of Hyperion Therapeutics will add two rare-disease drugs to its portfolio.

White House "superbug" plan has five-year goal

The White House's National Action Plan for Reducing Antibiotic-Resistant Bacteria proposal includes $1.2 billion in funding to reduce superbug infections and develop new diagnostics.

Five things for pharma marketers to know: Monday, March 30

Five things for pharma marketers to know: Monday, March 30

By

UnitedHealth Group buys PBM Catamaran; Sanofi launches Toujeo; Teva acquires Auspex Pharmaceuticals

Shire and Cincinnati Children's Hospital team up in rare diseases

Shire and Cincinnati Children's Hospital team up in rare diseases

By

The duo hope to begin testing a new treatment within three years.

Researchers say testosterone ads amount to disease mongering

An editorial says the industry's use of terms like "low T" and "andropause" are false and misleading.

Five things for pharma marketers to know: Thursday, March 26

Five things for pharma marketers to know: Thursday, March 26

By

Regeneron's Eylea won its fourth indication; Sun Pharma wants to revive trust in its products; confidentiality agreements keep Amgen from telling patients their cancer risk

Bristol-Myers Squibb licenses autoimmune program from Novo Nordisk

The drugmaker inks deal with Novo Nordisk to access its biologic discovery research platform.

Five things for pharma marketers to know: Wednesday, March 25

Five things for pharma marketers to know: Wednesday, March 25

By

Keytruda trial stopped due to positive results; new bill proposes continuing FDA rare pediatric voucher program; AstraZeneca signs five-year research pact with Harvard Stem Cell Institute

The New Holistic Approach to Leveraging a Multi-Channel Contact Center

The New Holistic Approach to Leveraging a Multi-Channel Contact Center

Delivering smarter dynamic communications rather than static timed communications based on self-reported data can help connect patients to information and support that drive brand loyalty and program success.

Pharma DTC spending jumps almost 21% in 2014

Pharma DTC spending jumps almost 21% in 2014

By

Nielsen data shows pharma spent $4.5 billion on DTC ads last year.

Harrison and Star names co-president

Mario Muredda and Mardene Miller will serve as co-presidents at the healthcare marketing agency.

Five things for pharma marketers to know: Monday, March 23

Five things for pharma marketers to know: Monday, March 23

By

Eleven new drugs with blockbuster potential are expected to launch this year; a bill would require FDA to quickly review drugs approved in the EU; Biogen reinforces its focus on hard-to-treat diseases

Five things for pharma marketers to know: Friday, March 20

Five things for pharma marketers to know: Friday, March 20

By

A judge rules against Amgen in Neupogen case; FDA advisory panel recommends Breio Ellipta for adults with asthma; AstraZeneca partners with Daiichi Sankyo to sell Movantik

ASCO wants to talk value when talking cancer

ASCO wants to talk value when talking cancer

By

An American Society of Clinical Oncology report shows the organization wants healthcare professionals to think in terms of value.

The Patient Abroad: An Exploration of the Motivations and Impact of Medical Tourism

The Patient Abroad: An Exploration of the Motivations and Impact of Medical Tourism

As global healthcare borders become increasingly blurred, the internationally mobile patient may become a standard patient segment considered in healthcare market research.

Sanofi R&D lead takes aim at global drug regulations

The Paris-based drugmaker's global president of R&D said that jumping through different and inconsistent regulatory hoops puts an "enormous" cost on drugmakers.

Five things for pharma marketers to know: Thursday, March 19

Five things for pharma marketers to know: Thursday, March 19

By

A Florida Congressman introduced a bill that would expand patent protections; Novo Nordisk expects to increase diabetes medication prices; AbbVie expanded its Alzheimer's research

US pharma market value projected to be $550 billion in five years

US pharma market value projected to be $550 billion in five years

By

Oncology and diabetes medications are expected to be major areas of growth.

What's Your Connected Health Strategy?

What's Your Connected Health Strategy?

At SXSW, for the first time, health wasn't a breakout topic, but rather a "break-in" topic that had the attention of just about every presenter and attendee.

Pfizer takes issue with Little Remedies

The drugmaker, which markets the Dimetapp cough and cold line, sent a complaint to the Better Business Bureaus.

Five things for pharma marketers to know: Wednesday, March 18

Five things for pharma marketers to know: Wednesday, March 18

By

GlaxoSmithKline respiratory drug's safety profile will be evaluated by FDA advisory panel; Actavis axes 400 New York jobs; physician testifies that he falsified Diovan clinical trial data

23andMe will harness genetic research in new drug discovery unit

23andMe will harness genetic research in new drug discovery unit

By

The personal genetics company created a therapeutics group to extricate new drug targets from its research database.

Customizing HCP Data In a Challenging Healthcare Environment

Customizing HCP Data In a Challenging Healthcare Environment

Traditional tactics of connecting with physicians are quickly becoming obsolete.

Obesity medications still a hard sell

Increased FDA scrutiny has not garnered trust for the new medications.

Five things for pharma marketers to know: Tuesday, March 17

Five things for pharma marketers to know: Tuesday, March 17

By

Interim results show cancer drug Imbruvica works well with other treatments; two studies show pricey new HCV medications are cost effective; the American College of Physicians wants less cardiac testing

FDA approves Boston Scientific atrial fibrillation device

The approval follows three advisory panel reviews and a complete response letter.

 

Did you miss January's Top 40 Healthcare Transformers issue? Read how these inventors, strategists, entrepreneurs and wonks are challenging, disrupting and otherwise transforming the healthcare business. And join us April 30 to honor them at the Transforming Healthcare Dinner. Click here.

Email Newsletters